China Resources Pharmaceutical Group Limited (Stock Code: 3320) announced that Tasly Pharmaceutical Group Co., Ltd., listed on the Shanghai Stock Exchange, released its unaudited financial report for the nine months ended 30 September 2025. Tasly Pharmaceutical is 28% owned through a non-wholly-owned subsidiary of China Resources Pharmaceutical Group Limited and is accounted for as a subsidiary.

According to the disclosure, Tasly Pharmaceutical recorded revenue of RMB 6.31 billion for the period, compared with RMB 6.46 billion for the same period last year. Net profit stood at RMB 992.55 million, compared with RMB 828.14 million for the prior-year period. Net cash flow increased by RMB 365.73 million, compared with a decrease of RMB 1.18 billion in the same period of 2024. Cash and cash equivalents at the end of the period amounted to RMB 1.18 billion, compared with RMB 1.02 billion at the same point last year.

As of 30 September 2025, Tasly Pharmaceutical’s total assets were RMB 14.96 billion, and total liabilities were RMB 2.46 billion, leading to owner’s equity of RMB 12.50 billion. The announcement noted that these figures are based on PRC Generally Accepted Accounting Principles and have not been reviewed or audited.

Further details are available in Tasly Pharmaceutical’s quarterly disclosures on the Shanghai Stock Exchange website. The announcement advises shareholders and investors to exercise caution when interpreting the relevant data.